SecBot SecBot
SECBOTREPLAY Home › Report › CLDX

CLDX · Celldex reported Q1 2026 EPS of -$1.18 (miss vs -$1.13 consensus) and…

Celldex Therapeutics, Inc. · PRESS-RELEASE filed May 7, 2026 at 16:01 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed May 7, 2026 at 16:01 ET

Celldex reported Q1 2026 EPS of -$1.18 (miss vs -$1.13 consensus) and revenue of $15K (miss vs $861K), reflecting widening losses as the company invests heavily in its pipeline. Positively, the company completed enrollment six months ahead of schedule in its Phase 3 barzolvolimab CSU studies, with topline data expected in Q4 2026 and a BLA submission planned for 2027, and strengthened its balance sheet with a $345M public offering in April. The mixed report balances near-term financial deterioration against significant pipeline progress and a cash runway through 2028.

  • EPS of -$1.18 vs consensus -$1.13 (miss of -4.4%)
  • Revenue of $15K vs consensus $861K (miss, but pre-revenue biotech)
  • Net loss widened to $78.7M from $53.8M in Q1 2025
  • Enrollment completed six months ahead of guidance in Phase 3 CSU studies (EMBARQ-CSU1 and 2, n=1,939 patients)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access